Menu Search
Equities

CEL-SCI Corp

CVM:ASQ

CEL-SCI Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.12
  • Today's Change0.000 / 0.00%
  • Shares traded155.90k
  • 1 Year change-13.85%
  • Beta0.6514
Data delayed at least 15 minutes, as of Sep 19 2024 16:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year CEL-SCI Corp had revenues remain flat at 0.00, though the company grew net income from a loss of 36.70m to a smaller loss of 32.19m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-100.88%
Return on equity-250.20%
Return on investment-124.78%
More ▼

Cash flow in USDView more

In 2023, cash reserves at CEL-SCI Corp fell by 18.53m. Cash Flow from Financing totalled 4.69m or -- of revenues. In addition the company used 22.85m for operations while cash used for investing totalled 372.26k.
Cash flow per share-0.4866
Price/Cash flow per share--
Book value per share0.1562
Tangible book value per share0.153
More ▼

Balance sheet in USDView more

CEL-SCI Corp has a Debt to Total Capital ratio of 55.17%, a lower figure than the previous year's 70.37%.
Current ratio0.6433
Quick ratio0.1793
Total debt/total equity1.23
Total debt/total capital0.5517
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.